We also report here that MG132 has beneficial effects, reversing cellular pathological phenotypes in HGPS fibroblasts and decreasing progerin and SRSF‐1 levels in iPSC‐derived MSC and VSMC from HGPS patients' fibroblasts. The gene discussed is LMNA; the disease is Hutchinson-Gilford progeria syndrome.